CARDIOSOLV ABLATION TECHNOLOGIES, INC.
Simulation-based software platform for predicting optimal catheter ablation targets in ventricular tachycardia patients
- Sector
- Medtech
- Headquarters
- BALTIMORE, MD
- Founded
- 2012
- Latest Form D
- $52K, Feb 2017
- Total capital
- $3.7M
- Federal grants
- $3.6M
- 4 awards · 2015–2021
- Rank in peer group#25 of 53
- Private capital raised
- $52K
- 1 Form D · last Feb 2017
- 116 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 5
- 3 pending · first 2019
- Rank in peer group#8 of 53
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Towards virtual laboratory for optimizing cardiac rhythm$870K
- Federal grantHealth and Human S · Phase II · Towards virtual laboratory for optimizing cardiac rhythm$1.4M
- Federal grantHealth and Human S · Phase II · Towards virtual laboratory for optimizing cardiac rhythm$669K
- Private capital raisedForm D · SEC · 1st filing$52K
- Federal grantHealth and Human S · Phase II · Towards virtual laboratory for optimal patient-specific cardiac resynchronization$666K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
22months
from CARDIOSOLV ABLATION TECHNOLOGIES, INC.’s first federal award to its first private round.
- First federal award · May 2015
- Health and Human S · $666K
- First Form D · Feb 2017
- $52K · 1st Form D
- Awards before first raise
- 1 award
An association in public records, not a cause or a prediction.
Standing among 53 peers
Line = medianMedtech · Software
- Federal grants#25 · top 47%
- Granted patents#8 · top 15%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Brock TiceDirectorNamed in SEC Form D filings
- Natalia TrayanovaDirectorNamed in SEC Form D filings
- Scott KokonesExecutive Officer, DirectorNamed in SEC Form D filings
- Steven GirouardDirectorNamed in SEC Form D filings
- Steven LaporteDirectorNamed in SEC Form D filings
- Vincent OwensExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 5 granted of 8- GrantedSystem And Method For Cardiac AblationUSPTOUS 11,839,459
- PendingSystems And Methods For Identifying Optimized Ablation Targets For Treating And Preventing Arrhythmias Sustained By Reentrant CircuitUSPTOApplication 18080790
- GrantedSystems And Methods For Identifying Optimized Ablation Targets For Treating And Preventing Arrhythmias Sustained By Reentrant CircuitUSPTOUS 11,532,078
Show all 8 patent records
- System And Method For Cardiac AblationDec 12, 2023 · US 11,839,459Granted
- Systems And Methods For Identifying Optimized Ablation Targets For Treating And Preventing Arrhythmias Sustained By Reentrant CircuitJun 8, 2023 · Application 18080790Pending
- Systems And Methods For Identifying Optimized Ablation Targets For Treating And Preventing Arrhythmias Sustained By Reentrant CircuitDec 20, 2022 · US 11,532,078Granted
- System And Method For Cardiac AblationFeb 23, 2021 · US 10,925,511Granted
- Systems And Methods For Identifying Optimized Ablation Targets For Treating And Preventing Arrhythmias Sustained By Reentrant CircuitJun 9, 2020 · US 10,679,348Granted
- Systems And Methods For Identifying Optimized Ablation Targets For Treating And Preventing Arrhythmias Sustained By Reentrant CircuitsSep 3, 2019 · US 10,402,966Granted
- Prediction Of Optimal Ablation Targets For Left Atrial Flutter In Patient Specific Models Using The Minimum Cut AlgorithmApplication 62262874Pending
- System And Method For Cardiac AblationApplication PCTUS2015041999Pending
Related companies, and why
- WEARIFI, INC.Similar federal contract value in Medtech · null in contracts
- AIROMATIX INC.Similar federal contract value in Medtech · null in contracts
- Cipher Skin, Inc.Similar federal contract value in Medtech · null in contracts
- LIMAX BIOSCIENCES INCSimilar federal contract value in Medtech · null in contracts
- HistoSonics, Inc.Similar federal contract value in Medtech · null in contracts
- Forest Devices, IncSimilar federal contract value in Medtech · null in contracts
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .